Regeneron wins bid to buy 23andMe out of bankruptcy
Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the successful bidder in a court-run auction.
Regeneron's offer, which is still subject to court and regulatory approvals, is a bet it can do what 23andMe couldn't and mine the troves of genetics data the testing firm collects to discover new drug targets. Regeneron plans to continue 23andMe's consumer genome services — a task made easier by its decade of experience sequencing the DNA of millions of people through its genetics center.
'We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their own DNA and how to improve their personal health, while furthering Regeneron's efforts to use large-scale genetics research to improve the way society treats and prevents illness overall,' George Yancopoulos, Regeneron's co-founder and chief scientist, said in a statement.
Under the proposed deal, Regeneron will pay $256 million to acquire 'substantially all' of 23andMe's assets, including its personal genome service, health and research service and biobank. It will also offer jobs to all of the employees at those business units.
The purchase would not include the telehealth business Lemonaid Health, which 23andMe will wind down.
Regeneron expects the deal will close in the third quarter, assuming it obtains all the necessary approvals. An ombudsman appointed by the bankruptcy court will review the transaction to assess how it might affect the privacy of individuals who previously used 23andMe to sequence their genome. A report from that review is due to the court by June 10, and a hearing is set for June 17.
In a statement, Aris Baras, head of the Regeneron Genetics Center, said the company is "committed to protecting the 23andMe dataset with our high standards of data privacy, security and ethical oversight and will advance its full potential to improve human health."
The center, which Regeneron launched in 2013, has uncovered more than two dozen novel drug targets by combing through its genome sequencing database. Among them are gene mutations associated with lower risk of obesity and liver disease, as well as a specific variant in the BRCA gene linked to breast and ovarian cancers.
The bankruptcy sale is a quiet end for a company that, at its peak, was worth some $6 billion. Co-founded by Anne Wojcicki in 2006, the firm built a brand that became synonymous with personal DNA testing. But it had ambitions to use that data to develop drugs, inking an R&D alliance with GSK in 2018 and then later building its own pipeline of experimental medicines.
Recent years have been harder on 23andMe, though. Declining demand for its consumer tests eroded its financial health and share price to the point Wojcicki attempted to take the company private. Her offer was rejected by the board, members of which later resigned to avoid a 'protracted and distracting difference of view' with Wojcicki.
After laying off 40% of its staff in November, the firm filed for Chapter 11 bankruptcy in March.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Omega's Otello Stampacchia on the ‘reset' changing biotech for the better
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Otello Stampacchia has watched the biotechnology industry survive many dark days in the two decades he's led one of its premier investment firms. Stampacchia formed Omega Funds in 2004, just a few years before the Great Recession caused a lengthy pullback in biotech investment. An exuberant period, during which a record number of drug companies went public, followed, only to later give way to another downturn that again tested the fortitude of biotech investors. Companies and their backers have a new set of challenges in 2025. Layoffs and leadership changes at public health agencies, competitive pressure from China and cuts to U.S. science funding have left biotech startups with a state of disquietude. Initial public offerings are harder than ever to price. Many public companies are worth less than their cash holdings, and face growing pressure from investors to shut down. And politics have seeped into science, eroding confidence in proven medical interventions like vaccines. Still, Stampacchia, whose firm raised a $647 million fund in July, is optimistic that better days lie ahead for biotech. The industry needs a reset that will 'lead to the greater good,' he told BioPharma Dive. 'This is medicine, and medicine sometimes tastes bitter,' Stampacchia said. BioPharma Dive spoke with Stampacchia about biotech investing. The following conversation has been lightly edited and condensed for clarity. BIOPHARMA DIVE: How has the slowdown in biotech IPOs affected your decision-making as an investor? OTELLO STAMPACCHIA: We like to tell our companies to stay private for longer, if possible. It's been more than five years now that we've been operating under the assumption that the IPO market should not be our road to a potential exit, which is usually via some acquisition. With M&A, you're selling to sophisticated buyers who know what they want. In the IPO market in our space, you're selling to relatively sophisticated public investors. But there's a lot of other variables that come into play — interest rates, the environment and so on. Generalists have basically deserted the space for quite a bit now, because there's a more attractive, in their opinion, risk-reward profile somewhere else. Has anything changed this year, when IPO activity appears especially slow? STAMPACCHIA: What we are seeing — and this could lead to some changes, actually — is the repercussions of some of these public investors being somewhat distressed. These were investors people traditionally used to go to syndicate the later-stage rounds. That's going to become a lot harder, which is going to make valuations more attractive for those later-stage rounds. So we are doing a bit of a tactical reallocation toward that later-stage opportunity set, because it's quite an interesting sweet spot. What do you make of investors pressuring struggling, publicly traded biotechs to close and return cash to shareholders? STAMPACCHIA: Necessity is the mother of all invention, as they say. There is a trend about not willing to give management the benefit of the doubt anymore. What you are seeing is a return to discipline, which has been quite a bit loose in the years where everybody could go public. Capital was abundant, interest rates were lower, all that. It all stems from the fact these public investors are suffering themselves. As a result, they need more liquidity, and some of these stocks are illiquid. It's more efficient to return that cash to shareholders. Each situation is a little bit different, but the reality is these companies all burn cash. If the cash is not going towards clinical programs that could potentially deliver either stock price appreciation or, even better, an M&A exit, it's a logical and rational decision to try to get some of the cash back. Overall, the market is trying to be more rational than it has been in the past. In the long term, it's not pretty when you're the employee of a company that is having to wind down. But on the macro level, it's kind of healthy. What can be done earlier to make sure fewer companies end up in this spot? STAMPACCHIA: The issue is the step where the company goes from a stricter governance model, which is what we try to implement as venture investors. A stricter governance model implies a very close collaboration between those investors, the board members and management. And that collaboration should — not always, but should — result in a tighter screw on what programs get funded and go forward, and the bar for those programs to move forward. When that collaboration and governance starts to become looser, some of these problems emerge. Companies spend money on unproductive projects, raise more money than they should, or don't raise enough. If I were to think, what should we do differently, it would be to ensure that control, governance and collaboration between those two important constituencies — the providers and users of capital — remains very tight for longer. A dirty little secret in the industry is that the reason companies love to go public are twofold: One is to get access to other sources of capital, because there's only so much money on the private side. The other, in my opinion, is that they can eventually get rid of their venture investors on the board. We have certain practices, which are not always correct, but they're usually fairly accurate, as they've been repeated hundreds of times across thousands of companies. Access to different sources of capital is great, but then you start losing some of the discipline, collaboration and governance. Does the politicization of mRNA vaccines and pullback in federal funding make you more hesitant to invest in vaccines? STAMPACCHIA: To be fully transparent, it's not like we have backed hundreds of vaccine companies. But the short answer is yes. The public health implications are more profound — obviously, measles and all that. The issue is vaccine hesitancy, which is potentially quite dangerous to society and public health. But from the very narrow investor mindset, it makes investing in that whole field much trickier. Across the spectrum in the community, there will be more hesitancy to invest in these companies. And that's not great. How have leadership changes at the FDA affected the sector, from your vantage point? STAMPACCHIA: We probably need a bit more distance and time to figure out how impactful these changes are. It is fair to say that there's a perception of instability, and perhaps even more importantly, a lack of consistency from the agency. All the statistics that I can find, as well as interactions our companies have with the agency, [show] the reviewers are doing their job. The issue is how is this going to play out in not just the short term, but the medium term, and how it will affect this perception of instability. Because perception of instability is instability in its own way. How has the inflow of biotech assets from China influenced your decision-making? STAMPACCHIA: This is relatively new, at least in terms of the percentage of these assets that have been licensed or acquired over the last two or three years. So there's quite an impact. And there's not a lot of visibility on companies in the country, versus we have a lot of visibility on companies in Europe. We need to do our job of competitive landscaping and positioning better. Fundamentally, and particularly for biologics, if there is a very validated target that could be improved by half-life or some heavy-duty iteration on the biological structure, and if it is a large enough market, somebody in China is probably doing it. And they have an advantage with the early stage trials. I don't think U.S. or European regulators understand that this is a massive advantage in enrolling patients early. That advantage is perhaps even more important than the advantages they have on [manufacturing] and iterating on biologics. The real speed is in the clinic to prove stuff. That has profound political implications for countries that want to maintain a healthy pharma/biotech industry. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
US eosinophilic oesophagitis market to reach $1.19bn by 2030
The eosinophilic oesophagitis (EoE) market in the US is forecast to grow from $202 million in 2020 to $1.19 billion in 2030, representing a robust compound annual growth rate of 19.4%, according to GlobalData. This growth will be fueled by the shift from off-label treatments such as proton pump inhibitors and compounded topical corticosteroids, towards more patient-friendly, US Food and Drug Association-approved therapies such as Sanofi/Regeneron's Dupixent (dupilumab), Takeda's Eohilia (budesonide oral suspension and Ellodi Pharmaceuticals' late-stage pipeline agent, APT-1011, an orally disintegrating tablet (ODT). Dupixent, first approved for EoE in adults and adolescents in 2022 then expanded in 2024 to treat children as young as one, has quickly established itself as a first-line biologic due to its strong efficacy, favourable safety profile and biweekly subcutaneous administration. Takeda's Eohilia, approved in 2024 as the first oral, targeted steroid for EoE, is expected to capture significant market share thanks to its ease of use compared to swallowed inhaler steroids. The anticipated launch of APT-1011, an ODT formulation of fluticasone propionate, will add further choice for patients, particularly in paediatrics where dosage form is a major factor in adherence. By 2030, Dupixent and Eohilia are expected to account for 75% of the US EoE market, with APT-1011 contributing 12.5%. The late-stage pipeline remains active, with more than 100 interventional trials initiated as of 2025, including novel biologics such as Amgen and AstraZeneca's co-developed Tezspire (tezepelumab), which targets upstream thymic stromal lymphopoietin (TSLP) signalling and next-generation corticosteroid formulations. Key opinion leaders interviewed by GlobalData noted a shift in clinical trial design toward multidomain endpoints that integrate histologic, endoscopic and patient-reported outcomes, moving beyond the traditional histologic remission threshold of 15 eosinophils or fewer per high-power field. This evolution reflects payer demand for more comprehensive measures of clinical benefit, particularly sustained improvement in swallowing function and quality of life. Despite the strong growth outlook, the market faces challenges. Payer step therapy and restrictive coverage criteria may limit broad adoption of biologics, while high list prices, such as Eohilia's reported launch price at approximately $5,250, could hinder uptake without robust cost-effectiveness data. Reliance on invasive endoscopy for diagnosis and monitoring also remains a significant burden, particularly in paediatric populations, though emerging tools such as the oesophageal string test and cytosponge could reduce procedure frequency. With multiple novel therapies expected to launch and the treatment paradigm shifting toward earlier, targeted intervention, GlobalData anticipates that the US EoE market will undergo rapid expansion over the forecast period, offering substantial opportunities for both biologic and small-molecule developers targeting this historically underserved condition. "US eosinophilic oesophagitis market to reach $1.19bn by 2030" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
13-08-2025
- Yahoo
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of US Personalized Medicine Market size & share revenue was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach around USD 252.93 Billion by 2034, at a CAGR of 17.32% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc., Precision Biologics, Danaher Corporation (Cepheid Inc.), GE HealthCare, Celera Diagnostics LLC, Decode Genetics Inc., Exact Sciences Corporation, IBM Corporation, Exagen Inc., Biogen, QIAGEN, Genentech Inc., 23andMe Inc., Asuragen Inc and others. Austin, TX, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'US Personalized Medicine Market Size, Trends and Insights By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition and Wellness), By Application (Oncology, CNS, Immunology, Respiratory, Liver, Rheumatology), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy, Others (Predictive Modeling, Imaging)), By End-user (Hospitals, Diagnostic Centers, Research & Academic Institutes), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' in its research database.'According to the latest research study, the demand of US Personalized Medicine Market size & share was valued at approximately USD 56.37 Billion in 2024 and is expected to reach USD 66.13 Billion in 2025 and is expected to reach a value of around USD 252.93 Billion by 2034, at a compound annual growth rate (CAGR) of about 17.32% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Overview As per the industry experts at CMI, the U.S. personalized medicine market is poised to witness a whopping CAGR in the forecast period. This could be attributed to genomic advancements such as next-generation sequencing that facilitate more accurate diagnostics and targeted therapies. The patients are asking for more customized approaches toward healthcare, thereby resulting in higher adoption of personalized medicine. Rise in incidences of chronic diseases such as cardiovascular diseases, cancer, and diabetes is accelerating the requirement of more personalized and effective treatment strategies. Conducive government policies coupled with raised funding for research and development activities are driving innovation. Key Trends & Drivers Technological Advancements and Higher Healthcare Spending to Spell Growth: Continuous advancements in data analytics, genomics, and bioinformatics are pushing the U.S. personalized medicine market forward. technologies such as CRISPR, NGS, and AI are transformingtreatment plans and diagnostics and making them more targeted as well as individualized. This innovation translates into patients' better understanding and customizes the treatment with better results. Also, as healthcare spending increases, the government as well as private agencies continue spending more dollars on the new technologies pertaining to modern medicine as mentioned above. Request a Customized Copy of the US Personalized Medicine Market Report @ Rise in Incidences of Chronic Diseases to Catalyze the U.S. Personalized Medicine Market: Chronic ailments cover conditions such as diabetes, cancer, and cardiovascular ailments. Personalized medicines are capable of being more effective in comparison with conventional types of treatment as they end up targeting the molecular and genetic basis of the conditions they address. Report Scope Feature of the Report Details Market Size in 2025 USD 66.13 Billion Projected Market Size in 2034 USD 252.93 Billion Market Size in 2024 USD 56.37 Billion CAGR Growth Rate 17.32% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product, Application, Technology, End-user and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Country Scope US Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the US Personalized Medicine report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the US Personalized Medicine report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the US Personalized Medicine Market Report @ SWOT Analysis Strengths: Genomic medicine is getting included in clinical practice. It is playing a vital role in diagnosing as well as treating the disease, thereby offering precise, individualized treatments providing better outcomes. Also, institutions are sharing data concerning clinical background, genetic information, and lifestyles across the providers, which facilitates the provision of more extensive and individualized treatment options, thereby helping to release new drugs in a faster way. Weaknesses: Tailored treatments such as sequencing, genetic tests, and targeted medications are costlier in comparison with conventional treatments. This factor does act as a substantial barrier to healthcare systems and insurance firms. Also, handling sensitive data does raise legal and ethical challenges pertaining to data privacy and security. These are some of the threats to the U.S. personalized medicine market. Opportunities: Amalgamating personalized medicine with digital health technologies such as remote monitoring and wearable devices is anticipated to improve patient engagement as well as treatment outcomes. Personalized medicine can also help in the identification of disease risks and promotion of preventive measures. Strategic partnerships amongst research organizations, academic institutions, and industry players have the ability to accelerate the adoption and development of personalized medicine. Threats: Lengthy processes of approvals and complicated regulatory requirements for personalized medicine products are likely to delay market access. The market players are bound to lose interest by the time the entire course of treatment or drugs gets approved and goes live. These are the major threats to the U.S. personalized medicine market. Request a Customized Copy of the US Personalized Medicine Market Report @ Key questions answered in this report: What is the size of the US Personalized Medicine market and what is its expected growth rate? What are the primary driving factors that push the US Personalized Medicine market forward? What are the US Personalized Medicine Industry's top companies? What are the different categories that the US Personalized Medicine Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the US Personalized Medicine market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ Key Developments The US personalized medicine market is witnessing a significant organic and inorganic expansion. Some of the key developments include – In May 2025, the scientists based in Philadelphia officiated a successful treatment for one of the rare genetic disorders in a nine-month-old baby using personalized CRISPR gene editing therapy. In January 2024, The US state of California announced that it would witness establishment of precision medicine center as the outcome of collaboration amongst the city of Bakersfield, the Kern Venture Group, and BIOS Health. The facility is bound to operate as a central location for R&D and brain clinical trials that use BIOS' adaptive dosage technology. In March 2023, Seagen announced that Pfizer acquired it for USD 229 in cash per Seagen share, totaling to USD 43 Billion enterprise value. Request a Customized Copy of the US Personalized Medicine Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'US Personalized Medicine Market Size, Trends and Insights By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Personalized Nutrition and Wellness), By Application (Oncology, CNS, Immunology, Respiratory, Liver, Rheumatology), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Gene Sequencing, Drug Discovery, Companion Diagnostics, Genetics, Liquid Biopsy, Others (Predictive Modeling, Imaging)), By End-user (Hospitals, Diagnostic Centers, Research & Academic Institutes), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034' Report at of the prominent players in the US Personalized Medicine Market: Illumina Inc. Precision Biologics Danaher Corporation (Cepheid Inc.) GE HealthCare Celera Diagnostics LLC Decode Genetics Inc. Exact Sciences Corporation IBM Corporation Exagen Inc. Biogen QIAGEN Genentech Inc. 23andMe Inc. Asuragen Inc. Others Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Induced Pluripotent Stem Cell (iPSC) Market: Induced Pluripotent Stem Cell (iPSC) Market Size, Trends and Insights By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others), By Application (Drug Development, Tissue Engineering & Regenerative Medicine, Disease Modelling, Toxicology Research), By End-Use (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Fabry Disease Treatment Market: Fabry Disease Treatment Market Size, Trends and Insights By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), Others), By Route of Administration (Intravenous Route, Oral Route), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Elastomeric Infusions Pumps Market: Elastomeric Infusions Pumps Market Size, Trends and Insights By Product (Variable Rate, Continuous Rate), By Application (Antibiotic/Antiviral Therapy, Chemotherapy, Pain Management, Others), By End-Use (Ambulatory Surgical Centers, Hospitals, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Duchenne Muscular Dystrophy Drugs Market: Duchenne Muscular Dystrophy Drugs Market Size, Trends and Insights By Drug Type (Exon skipping drugs, Corticosteroids, Gene therapy, Other drug types), By Route of Administration (Oral, Injectable), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Digital Microscopes Market: Digital Microscopes Market Size, Trends and Insights By Product Type (Digital Biological Microscopes, Electron Microscope, Digital Surgical Microscopes, Others (Digital Inspection Camera, and Others)), By Modality (Desktop Digital Microscope, Portable Digital Microscope), By Connectivity (Wired Digital Microscope, Wireless Digital Microscope), By Application (Research & Development, Life Science, Medical Diagnostics, Forensic Testing), By End User (Hospitals, Clinics, Biopharmaceutical Companies, Academic Research Institute, Others (Forensic and Pathology Laboratory)), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Adult Day Care Services Market: Adult Day Care Services Market Size, Trends and Insights By Services (Adult Social Day Services, Adult Day Healthcare Services, Specialized Day Care Services), By Service Provider (Private, Public), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Synthetic Blood Substitutes and Blood Product Market: Synthetic Blood Substitutes and Blood Product Market Size, Trends and Insights By Source (Human Blood, Animal Blood, Synthetic Polymers, Stem Cells, Others), By Type (Perfluorocarbon Based Product (PFC), Haemoglobin Based Oxygen Carrier, Synthetic Platelet, Recombinant Factor, Blood Expander), By Installation Type (Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, Others), By End-User (Hospitals and Clinics, Blood Banks, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Dental Prosthetics Market: Dental Prosthetics Market Size, Trends and Insights By Type (Crowns, Bridges, Abutments, Dentures, Others), By End-User (Solo Practices, DSO/Group Practices, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 The US Personalized Medicine Market is segmented as follows: By Product Personalized Medicine Diagnostics Personalized Medicine Therapeutics Personalized Nutrition and Wellness By Application Oncology CNS Immunology Respiratory Liver Rheumatology By Technology Big Data Analytics Artificial Intelligence Bioinformatics Gene Sequencing Drug Discovery Companion Diagnostics Genetics Liquid Biopsy Others (Predictive Modeling, Imaging) By End-user Hospitals Diagnostic Centers Research & Academic Institutes Click Here to Get a Free Sample Report of the US Personalized Medicine Market @ This US Personalized Medicine Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Key Players in This US Personalized Medicine Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Market Status of the US Personalized Medicine Market? What Was the Capacity, Production Value, Cost and PROFIT of the US Personalized Medicine Market? What Is the Current Market Status of the US Personalized Medicine Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of US Personalized Medicine Market by Considering Applications and Types? What Are Projections of the US Personalized Medicine Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is US Personalized Medicine Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On US Personalized Medicine Industry? What are Macroeconomic Environment Analysis Results? What Are Macroeconomic Environment Development Trends? What Are Market Dynamics of US Personalized Medicine Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for US Personalized Medicine Industry? Click Here to Access a Free Sample Report of the US Personalized Medicine Market @ Reasons to Purchase US Personalized Medicine Market Report US Personalized Medicine Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. US Personalized Medicine Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. US Personalized Medicine Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. US Personalized Medicine Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the US Personalized Medicine market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide US Personalized Medicine market analysis. The competitive environment of current and potential participants in the US Personalized Medicine market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide US Personalized Medicine market should find this report useful. The research will be useful to all market participants in the US Personalized Medicine industry. Managers in the US Personalized Medicine sector are interested in publishing up-to-date and projected data about the worldwide US Personalized Medicine market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in US Personalized Medicine products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the US Personalized Medicine Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium US Personalized Medicine Research Report | Fast Delivery Available - [220+ Pages] @ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
